This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


Delta-Fly Pharma, Inc.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2019/6/29
Profile

Delegates :
Kiyoshi Eshima, PhD,


Incorporated :
December  6 , 2010

Paid in Capital :
2795 Million yen  

Employees :

Address :
37-5 Nishikino, Miyajima, Kawauchi-cho TOKUSHIMA
〒771-0116

TEL/FAX :
+81-3-6231-1278 / +81-3-6231-1478

URL:
https://www.delta-flypharma.co.jp/index.html

Attachment :

Mission/Background :
Delta-Fly is a drug discovery startup that specializes in anticancer agents using module technology(discussed later). It aims to develop anticancer treatments gentle on the body and the wallet. Current president Kiyoshi Eshima established the company in December 2010 in Tokushima, gathering a team of colleagues with over 20 years' experience in anticancer agent development. The company listed on TSE Mothers in October 2018.

Technology & Business
Using its proprietary module technology, pharmaceutical company Delta-Fly conducts R&D into new anticancer agents. Module technology is a unique drug discovery method that takes the active ingredients (modules) of anticancer agents from existing drugs whose patents have expired or whose development was halted due to side effects and combines them to create new drugs with an improved balance of clinical efficacy and safety. Anticancer agents usually take over 10 years to develop. However, very little basic research is necessary in module technology, which lowers development risks and enables potential approval after R&D of six to eight years. The new agents are patentable as new drugs.
Products & Service
Products & Service Name
Stage
Outline
Milestone
DFP-10917 (Cell cycle regulator)
Phase3
Relapsed/refractory acute myeloid leukemia (AML)
Launch date scheduled for 2022
DFP-14323 (Cancer immuno modulator)
Phase2
Non-small cell lung cancer (NSCLC)
Launch date scheduled for 2023
DFP-11207 (Cancer cell metabolism regulator)
Phase1
Solid tumor (Pancreatic cancer, other)
Launch date scheduled for 2024
DFP-14927 (Polymeric agent of anti-tumor drug)
Phase1
Solid tumor, Hematopoietic tumor
Launch date scheduled for 2025
DFP-10825 (Oligonucleotide therapeutics)
Preclinical
Peritoneal disseminated metastatic cancer
Launch date scheduled for 2026
Highlights
DFP-10917: Delta-Fly resubmitted the protocol to the FDA, and began preparations to enroll patients for the Phase 3 study.
DFP-14323: To speed up the Phase 2 study that is currently underway by expanding the number of facilities.
DFP-11207: Phase 1 study and the food effect study was completed, thereafter was presented at ASCO.
DFP-14927: The FDA completed a safety review, and obtained IND approval.
DFP-10825: It started preparing to manufacture new API and formulations with Phase 1 study.

Hot news

Alliance strategy
The company would like to collaborate with pharmaceutical company in Europe and US in markets.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.